Global Liver Cancer Market Size Likely to Surpass at a CAGR of 14.5% By 2033

As per the current market research conducted by CMI Team, the global Liver Cancer Market size is expected to record a CAGR of 14.5% from 2024 to 2033. In 2024, the market size is projected to reach a valuation of USD 4.8 Billion. By 2033, the valuation is anticipated to reach USD 16.3 Billion.

Liver Cancer Market: Growth Factors and Dynamics

• Rising Incidence and Prevalence: The increasing occurrence of liver cancer, particularly hepatocellular carcinoma (HCC), is a primary driver, attributed to factors like chronic hepatitis B and C infections, alcoholic liver disease, and non-alcoholic fatty liver disease (NAFLD).

• Advancements in Treatment Modalities: Ongoing advancements in treatment options, including surgical interventions, ablation therapies, targeted therapies, and immunotherapies, contribute to the overall growth of the liver cancer market by providing more effective and diverse treatment choices.

• Increasing Emphasis on Early Detection: Growing awareness and initiatives for early detection of liver cancer through screening programs and diagnostic advancements are vital factors. Early detection enhances treatment outcomes and contributes to the overall growth of the market.

• Technological Innovations in Imaging: Continuous developments in imaging technologies, such as MRI and CT scans, aid in accurate diagnosis, staging, and monitoring of liver cancer. These innovations play a crucial role in driving the demand for diagnostic tools within the market.

• Rising Healthcare Expenditure: Increased healthcare expenditure, both by governments and individuals, supports the accessibility and adoption of advanced treatments for liver cancer. This financial investment contributes to the market’s growth, fostering research, and the development of new therapeutic options.

• Risk Factors and Lifestyle Changes: Changing lifestyles, including unhealthy dietary habits, sedentary lifestyles, and an increase in risk factors such as obesity and diabetes, contribute to the growing incidence of liver cancer, further propelling the demand for effective treatments and driving market growth.

• Global Initiatives for Viral Hepatitis Control: Global efforts to control viral hepatitis, a major risk factor for liver cancer, through vaccination programs, awareness campaigns, and improved access to antiviral treatments positively impact the market. These initiatives aim to reduce the incidence of hepatitis B and C, subsequently lowering the burden of liver cancer.

• Expanding Research on Biomarkers and Personalized Medicine: Ongoing research on biomarkers for liver cancer and the advent of personalized medicine contribute to the market’s growth. Identification of specific molecular targets and the development of targeted therapies tailored to individual patients enhance treatment efficacy and drive innovation in the liver cancer market.

Liver Cancer Market: Partnership and Acquisitions

• In 2022, AstraZeneca’s immunotherapy combinations, Imfinzi (durvalumab) and Imjudo (tremelimumab), received European Union approval for advanced liver and lung cancers. Imfinzi with Imjudo is approved for 1st-line treatment of advanced hepatocellular carcinoma, and Imfinzi with Imjudo and platinum-based chemotherapy is authorized for metastatic non-small cell lung cancer treatment.

• In 2023, MedGenome introduced a genetic test for Facioscapulohumeral Muscular Dystrophy diagnosis in India, broadening its product portfolio. The move reflects escalating competition in the market, highlighting the company’s commitment to addressing unmet medical needs and expanding its presence in the genetic testing sector.

Report Scope

Liver Cancer Market: COVID-19 Analysis

The COVID-19 pandemic has had a significant impact on the Liver Cancer Market, with the industry experiencing both positive and negative effects. Here are some of the key impacts:

• Disruption in Diagnosis and Treatment: The COVID-19 pandemic led to disruptions in routine medical services, including delayed diagnoses and treatments for liver cancer patients, as healthcare resources were redirected towards managing the pandemic.

• Clinical Trial Delays: Many clinical trials investigating new therapies for liver cancer were delayed or temporarily halted due to the challenges posed by the pandemic, affecting the progression of novel treatment options.

• Resumption of Screening Programs: With the easing of pandemic-related restrictions, there is a concerted effort to resume and strengthen screening programs for liver cancer, facilitating early detection and timely intervention.

• Telemedicine Adoption: The increased adoption of telemedicine and virtual consultations has facilitated ongoing patient care, enabling healthcare providers to monitor and manage liver cancer patients remotely, ensuring continuity of treatment.

• Accelerated Clinical Trial Activities: Efforts are underway to expedite and prioritize liver cancer-related clinical trials, aiming to compensate for delays during the pandemic and accelerate the development of new and innovative treatment options.

• Focus on Patient Education and Awareness: There is an increased emphasis on educating patients about the importance of regular check-ups, screenings, and adherence to treatment plans to mitigate the impact of delayed diagnoses and ensure better outcomes.

• Enhanced Research Collaboration: Collaborative efforts among pharmaceutical companies, research institutions, and healthcare organizations have intensified, aiming to advance liver cancer research, develop novel therapies, and address challenges posed by the pandemic, fostering a resilient recovery in the market.

In conclusion, the COVID-19 pandemic has had a mixed impact on the Liver Cancer Market, with some challenges and opportunities arising from the pandemic.

List of the prominent players in the Liver Cancer Market:

• Bayer AG
• Bristol Myers Squibb Company
• Eli Lilly and Company
• Exelixis Inc.
• Hoffmann-La Roche Ltd.
• Gilead Sciences Inc.
• Johnson & Johnson
• Merck & Co. Inc.
• Novartis AG
• Pfizer Inc.
• Sanofi S.A.
• Siemens Healthineers AG
• Sirtex Medical Limited
• Sorafenib (Nexavar)
• Taiho Pharmaceutical Co. Ltd.
• Others

The Liver Cancer Market is segmented as follows:

By Type

• Hepatocellular Carcinoma (HCC)
• Intrahepatic Cholangiocarcinoma
• Hepatoblastoma
• Angiosarcoma
• Others

By Treatment Modality

• Surgery
• Ablation Therapy
• Embolization Therapy
• Radiation Therapy
• Targeted Therapy
• Immunotherapy
• Chemotherapy

By End-User

• Hospitals
• Specialty Clinics
• Ambulatory Surgical Centers
• Cancer Research Institutes

Regional Coverage:

North America

• U.S.
• Canada
• Mexico
• Rest of North America

Europe

• Germany
• France
• U.K.
• Russia
• Italy
• Spain
• Netherlands
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• New Zealand
• Australia
• South Korea
• Taiwan
• Rest of Asia Pacific

The Middle East & Africa

• Saudi Arabia
• UAE
• Egypt
• Kuwait
• South Africa
• Rest of the Middle East & Africa

Latin America

• Brazil
• Argentina
• Rest of Latin America